AstraZeneca doubled the incidence of cerebral vein thrombosis - proven

Two independent groups of British scientists found that vaccination
against coronavirus with AstraZeneca increased the incidence of
cerebral vein thrombosis by about two times compared to
pre-vaccination values. The researchers estimate that vaccination
causes 1-3 excess cases per million people. Both the first and second
papers were published in PLOS Medicine. A few months after the
AstraZeneca coronavirus vaccine began to be used in Europe, it showed
side effects. One of them was thrombosis, which rarely, but still
affected young women. In April 2021, the European regulator listed
thrombosis as a rare side effect of AstraZeneca after the discovery
of this adverse reaction.
- Research 1 https://bit.ly/3hbM9og Association of COVID-19 vaccines
ChAdOx1 and BNT162b2 with major venous, arterial, or
thrombocytopenic events: A population-based cohort study of 46
million adults in England
- Research 2 https://bit.ly/3paXNUS First dose ChAdOx1 and BNT162b2
COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled
self-controlled case series study of 11.6 million individuals in England,
Scotland, and Wales

You are viewing proxied material from gopher.erb.pw. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.